B-type Natriuretic Peptides in Acute Coronary Syndromes: Implications in an Aging Population

Authors

  • Selim R. Krim MD,

    Corresponding author
    1. Division of Cardiology, John Ochsner Heart and Vascular Institute, Ochsner Clinic Foundation, New Orleans, LA
    • Division of Cardiology, John Ochsner Heart and Vascular Institute, Ochsner Clinic Foundation, 1514 Jefferson Highway, New Orleans, LA 70121
    Search for more papers by this author
  • Rey P. Vivo MD,

    1. Division of Cardiology, University of Texas Medical Branch, Galveston, TX
    2. Methodist Debakey Heart and Vascular Center, Houston, TX
    Search for more papers by this author
  • James A. de Lemos MD

    1. Donald W. Reynolds Cardiovascular Clinical Research Center, University of Texas Southwestern Medical Center, Dallas, Texas
    Search for more papers by this author

Abstract

B-type natriuretic peptide (BNP) and N-terminal-proBNP (NT-proBNP) are increasingly recognized as prognostic markers in patients with acute coronary syndrome (ACS). The need for novel and more effective tools for risk assessment cannot be more emphasized than in older patients with ACS given their atypical presentation, multiple comorbidities, and higher risk for mortality and morbidity. Accurate interpretation of B-type NP values in older patients with ACS, however, may be confounded by several aging-related physiologic changes. Advanced age, reduction in body mass, and kidney function and anemia have been associated with higher BNP and NT-proBNP concentrations, and may create challenges with interpreting NP levels in the elderly. This review highlights the need to better understand the physiology of BNP and NT-proBNP in older individuals and their prognostic value in older patients with ACS. Clin. Cardiol. 2012 doi: 10.1002/clc.22035

Dr. de Lemos has received grant support from Roche Diagnostics and Abbott Diagnostics. The authors have no other funding, financial relationships, or conflicts of interest to disclose.

Ancillary